Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis

References

• The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Coronavirus COVID-19 global cases [Internet]. Cent. Syst. Sci. Eng. Johns Hopkins Univ. Coronavirus COVID-19 Glob. cases. 2020. p. 1–9. The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Coronavirus COVID-19 global cases.
   Google Scholar
• Mehta N, Kalra A, Nowacki AS, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 [cited 2020 Jul 9];5(9):1020. Available from: https://pubmed.ncbi.nlm.nih.gov/32369097/
   Web of Science ®Google Scholar
• Vaduganathan M, Vardeny O, Michel T, et al. Renin–angiotensin–aldosterone system inhibitors in patients with covid-19. N Engl J Med [Internet]. 2020 [cited 2020 Jul 9];382(17):1653–1659. Available from: https://pubmed.ncbi.nlm.nih.gov/32227760/
   PubMed Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [Internet]. Lancet Respir Med. Lancet Publishing Group. 2020 [cited 2020 Jul 9];8(4):e21 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118626/
   PubMed Web of Science ®Google Scholar
• Rami S. Re: preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ. 2020 Mar 3 [cited 2020 Jul 9]. Available from:. https://www.bmj.com/content/368/bmj.m810/rr–2
   Google Scholar
• Sarzani R, Giulietti F, Di Pentima C, et al. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. Am J Physiol Lung Cell Mol Physiol. 2020;319:L325–L336.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020 [cited 2020 Jul 9];126:1671–1681. Available from: https://pubmed.ncbi.nlm.nih.gov/32302265/
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 [cited 2020 Jul 9];355. Available from: https://pubmed.ncbi.nlm.nih.gov/27733354/
   Google Scholar
• Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
   Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses [Internet]. Br Med J BMJ. 2003 [cited 2020 Jul 9];327(7414):557–560. Available from:: https://pubmed.ncbi.nlm.nih.gov/12958120/
   PubMed Web of Science ®Google Scholar
• html DW http://mason. gmu. edu/~ dwilsonb/ma., 2005 undefined. Meta-analysis macros for SAS, SPSS, and Stata (Version 2005.05. 23).
   Google Scholar
• Amaouche S, Letaief Z, Buls N, et al. The relation between acei/arb use and Covid-19 severity in rt-pcr-confirmed cases: a retrospective case-control study [Internet]. 2020 [cited 2020 Ju n1]. Available from: https://www.researchsquare.com/article/rs–33177/v1.
   Google Scholar
• Mancia G, Rea F, Ludergnani M, et al. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med [Internet]. 2020 [cited 2020 Jul 9];382(25):2431–2440. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2006923
   PubMed Web of Science ®Google Scholar
• Giorgi Rossi Epidemiologist P, Marino Statistician M, Formisano Statistician D, et al. Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. MedRXiv. 2020 Apr 16 [cited 2020 Jul 11]. Doi:10.1101/2020.04.13.20063545
   Google Scholar
• Dauchet L, Lambert M, Gauthier V, et al. ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments. The ACER-COVID study [Internet]. medRxiv. Cold Spring Harbor Laboratory Press. 2020 [cited 2020 Jul 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.04.28.20078071
   Google Scholar
• Yan H, Valdes AM, Vijay A, et al. Role of drugs affecting the renin-angiotensin-aldosterone system on susceptibility and severity of COVID-19: a large case-control study from Zheijang Province, China. medRxiv. Cold Spring Harbor Laboratory Press. 2020 [cited 2020 Jul 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.04.24.20077875
   Google Scholar
• Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med [Internet]. 2020 [cited 2020 Jul 9];382(25):e102. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2007621
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 [cited 2020 Jul 9];339. Available from: http://www.bmj.com/
   Web of Science ®Google Scholar
• Khera R, Clark C, Lu Y, et al. Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease–19.
   Google Scholar
• Li J, Wang X, Chen J, et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for Coronavirus Disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. [cited 2020 Jul 9] 2020;5(7):825. Available from: https://jamanetwork.com/
   Web of Science ®Google Scholar
• Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv 2020 [cited 2020 Jul 9];2020.03.20.20039586. DOI:10.1101/2020.03.20.20039586
   Google Scholar
• Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension [Internet]. Emerging Microbes Infect. Taylor and Francis Ltd. 2020 [cited 2020 Jul 9];9(1):757–760. Available from: https://pubmed.ncbi.nlm.nih.gov/32228222/
   PubMed Web of Science ®Google Scholar
• Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 [cited 2020 Jul 9] ;48:E004. Available from: https://pubmed.ncbi.nlm.nih.gov/32120458/
   Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of covid-19. N Engl J Med [Internet]. 2020 [cited 2020 Jul 9];382(25):2441–2448. Available from: https://pubmed.ncbi.nlm.nih.gov/32356628/
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. J Am Med Assoc 2020 [cited 2020 Jul 9];323:2052–2059. Available from: https://pubmed.ncbi.nlm.nih.gov/32320003/
   PubMed Web of Science ®Google Scholar
• Selçuk M, Çınar T, Keskin M, et al. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Clin Exp Hypertens. 2020 [ [cited 2020 Jul 11];1–5. Available from: https://www.tandfonline.com/doi/full/10.1080/10641963.2020.1783549
   Web of Science ®Google Scholar
• Tedeschi S, Giannella M, Bartoletti M, et al. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for coronavirus disease 2019. Clin Infect Dis [Internet]. 2003;71(15):899–901.
   Google Scholar
• Yang G, Tan Z, Zhou L, et al. Effects of angiotensin ii receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertens [cited 2020 Jul 9] 2020;76:51–58. Available from: https://pubmed.ncbi.nlm.nih.gov/32348166/
   PubMed Web of Science ®Google Scholar
• Bean DM, Kraljevic Z, Searle T, et al. ACE-inhibitors and angiotensin-2 receptor blockers are not associated with severe SARS- COVID19 infection in a multi-site UK acute hospital trust. medRxiv. 2020 [cited 2020 Jul 9];2020: 04.07.20056788. DOI:10.1101/2020.04.07.20056788.
   Google Scholar
• Zeng Z, Sha T, Zhang Y, et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study [Internet]. medRxiv. 2020 [cited 2020 Jul 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.04.06.20054825
   Google Scholar
• Felice C, Nardin C, Di Tanna GL, et al. Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives. Am J Hypertens. 2020 Jun 8 [cited 2020 Jul 11]; Available from: https://academic.oup.com/ajh/article-abstract/doi/10.1093/ajh/hpaa096/5854703
   Web of Science ®Google Scholar
• Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. [cited 2020 Jul 9] 2020;201(11):1380–1388. Available from:: https://pubmed.ncbi.nlm.nih.gov/32275452/
   PubMed Web of Science ®Google Scholar
• Fosbøl EL, Butt JH, Østergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. J Am Med Assoc. [cited 2020 Jul 9] 2020;324(2):168. Available from: https://jamanetwork.com/
   Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. [cited 2020 Jul 9] 2020;5(7):811. Available from: https://jamanetwork.com/
   Web of Science ®Google Scholar
• Hu J, Zhang X, Zhang X, et al. COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no infulence on the clinical severity and outcome. 2020 2020 May 28 [cited 2020 Jul 11]. DOI:10.1016/j.jinf.2020.05.056.
   Google Scholar
• Ip A, Parikh K, Parrillo JE, et al. Hypertension and renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. medRxiv. 2020 [cited 2020 Jul 9];2020. 04.24.20077388. DOI:10.1101/2020.04.24.20077388
   Google Scholar
• Jung S-Y, Choi JC, You S-H, et al. Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study. Clin Infect Dis [Internet]. 2020. DOI:10.1093/cid/ciaa624
   Web of Science ®Google Scholar
• Higgins JP, Thomas J, Chandler J, et al. (eds). Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019 Sep 23.
   Google Scholar
• HFSA/ACC/AHA statement addresses concerns re: using RAAS Antagonists in COVID-19 - American College of Cardiology [Internet]. 2020 Jun 1 [cited 2020 Aug 24]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid–19
   Google Scholar
• Amat-Santos I, … SS-M-J of the A, 2020 undefined. Ramipril in high risk patients with COVID-19. Elsevier [Internet]. 2020 Jun 1 [cited 2020 Aug 24]. Available from: https://www.sciencedirect.com/science/article/pii/S073510972035395X.
   Google Scholar
• Tedeschi S, Giannella M, Bartoletti M, et al. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020 Apr 27.
   Google Scholar
• ACE inhibitors or arbs discontinuation in context of SARS-CoV-2 pandemic - full text view - ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; [cited 2020 Aug 24]. Available from:. https://clinicaltrials.gov/ct2/show/NCT04329195?term=ARB%2C+ACE%2C+RAS&cond=COVID-19&draw=2&rank=1
   Google Scholar
• Effects of Discontinuing Renin-Angiotensin System Inhibitors In Patients with COVID-19 - full text view - ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; [cited 2020 Aug 24]. Available from:. https://clinicaltrials.gov/ct2/show/NCT04351581?term=ARB%2C+ACE%2C+RAS&cond=COVID-19&draw=2&rank=4
   Google Scholar
• Valsartan for prevention of acute respiratory distress syndrome in hospitalized patients with SARS-COV-2 (COVID-19) infection disease - full text view - ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; [cited 2020 Aug 24]. Available from:. https://clinicaltrials.gov/ct2/show/NCT04335786?term=ARB%2C+ACE%2C+RAS&cond=COVID-19&draw=2&rank=5
   Google Scholar
• Renin-angiotensin system inhibitors and COVID-19 - full text view - ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; [cited 2020 Aug 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT04331574?term=ARB%2C+ACE%2C+RAS&cond=COVID-19&draw=2&rank=3.
   Google Scholar